CELESTIMO trial shows mosunetuzumab plus lenalidomide boosts PFS in relapsed follicular lymphoma, supporting earlier-line outpatient, chemo-free care.
|Videos|April 24, 2017
Risk-Based Management of Follicular Lymphoma: Case 1
Risk-Based Management of Follicular Lymphoma
Advertisement
June 2015
A 75-year-old female presents to her physician with bilateral inguinal adenopathy. She is otherwise healthy.
- Laboratory findings: CBC count and LDH WNL
- CT scan shows scattered adenopathy in the pelvis, mesentery, retroperitoneal regions. The largest lymph node is 2.6 cm.
- Chest radiography, normal
- Bone marrow biopsy is negative
- Excisional biopsy, IHC staining for CD10 shows grade 1 follicular lymphoma
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
SOT106 Receives New FDA FTD and ODD in Sarcoma
2
Luciano Costa, MD, Discusses the Changing Treatment Paradigm in Myeloma
3
Dr Matous on Moving T-Cell Redirection Into Frontline Myeloma Care
4
Global Experts Define Consensus Criteria for Cure in Multiple Myeloma
5